GlassScriptPhysician profile
Thomas A Henderson
NPI 1740371020
$3,208.72
in general payments reported to CMS, 2019-2025
36 companies · $960 in 2025
The $960 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $178 · 2020: $26.14 · 2022: $226 · 2023: $798 · 2024: $1,021 · 2025: $960.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,779.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,778.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $424.11 | 2023-2025 | Jardiance, Synjardy, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $372.57 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $331.71 | 2023-2025 | Otezla, Repatha, Krystexxa |
| Novo Nordisk INC | $327.75 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $323.32 | 2022-2025 | |
| Pfizer INC. | $179.77 | 2023-2025 | |
| Lilly USA, LLC | $167.30 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $139.52 | 2019-2025 | Veozah, Myrbetriq |
| Esperion Therapeutics, INC. | $83.79 | 2022-2024 | Nexletol |
| Sanofi-Aventis U.S. LLC | $74.51 | 2019 | |
| Exact Sciences Corporation | $73.86 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boston Scientific Corporation | $62.48 | 2025 | Wavewriter Alpha Prime 16, General - Therapies |
| Kowa Pharmaceuticals America, INC. | $56.27 | 2022-2023 | Seglentis |
| Glaxosmithkline, LLC. | $48.57 | 2023-2025 | Shingrix, Arexvy |
| Sunovion Pharmaceuticals INC. | $39.82 | 2019-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $39.27 | 2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $37.83 | 2025 | |
| Aimmune Therapeutics, INC. | $36.42 | 2025 | Zenpep |
| Lucid Diagnostics INC. | $36.08 | 2025 | |
| Janssen Pharmaceuticals, INC | $33.49 | 2023 | Xarelto |
| Abiomed | $32.25 | 2025 | |
| Axsome Therapeutics, INC. | $26.57 | 2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.68 | 2024 | Caplyta |
| Edwards Lifesciences Corporation | $23.24 | 2025 | Sapien 3 Ultra Resilia |
| Corcept Therapeutics | $22.99 | 2025 | Korlym |
| Fidia Pharma USA INC. | $22.18 | 2025 | Triluron, Hymovis |
| Novartis Pharmaceuticals Corporation | $22.06 | 2022 | |
| Seqirus USA INC | $20.81 | 2025 | Fluad, Flucelvax |
| Sumitomo Pharma America, INC. | $20.69 | 2024 | Gemtesa |
| Biohaven Pharmaceutical Holding Company LTD. | $19.29 | 2022 | |
| Merck Sharp & Dohme LLC | $15.88 | 2023 | Belsomra |
| Inogen, INC. | $15.74 | 2022 | |
| Cleerly, INC. | $15.07 | 2024 | Cleerly Labs |
| Sanofi Pasteur INC. | $14.88 | 2019 | |
| Idorsia Pharmaceuticals US INC | $12.74 | 2023 | Quviviq |
| Amarin Pharma, INC. | $11.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Henderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.